New drug aims to stop anemia after stem cell transplants

NCT ID NCT07539779

Not yet recruiting Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug luspatercept can prevent severe anemia (low red blood cells) after a stem cell transplant in people with blood cancers and a bone marrow condition called myelofibrosis. About 196 adults will receive either luspatercept or standard supportive care. The goal is to see if luspatercept helps patients avoid needing blood transfusions and improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: luspatercept
What this could lead to: If it works, this could provide a new way to prevent severe anemia after stem cell transplant, reducing the need for blood transfusions and improving recovery.
What could go wrong: This is an early-phase study with only 196 participants. The drug may not work better than standard care, and side effects from luspatercept are possible. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES LUSPATERCEPT MYELOFIBROSIS，MF POOR ERYTHROID ENGRAFTMENT

Contacts and locations

Locations

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.